The Impact of Biologic Therapy on Quality of Life and Mental Health in Patients with Psoriasis

Psoriasis is a chronic immune-mediated inflammatory skin disease often associated with systemic inflammation and multiple comorbidities, resulting in a substantial negative impact on patients’ quality of life and mental health. In addition to cutaneous and joint involvement, patients frequently experience psychological distress, social stigma, and symptoms of anxiety and depression, which may be comparable in clinical relevance to the physical manifestations of the disease. In recent years, biologic therapies have become increasingly established in the treatment of psoriasis due to their targeted action on key inflammatory pathways involved in disease pathogenesis and their high clinical efficacy. Beyond improving disease severity, biologic agents have also been associated with meaningful improvements in health-related quality of life and mental health outcomes. Importantly, currently available evidence suggests that psychological and quality-of-life outcomes in psoriasis are influenced by multiple interacting clinical and psychosocial factors. This narrative review summarizes recent scientific evidence on the relationship between psoriasis, quality of life, and mental health, with particular emphasis on the impact of biologic therapy on these outcomes. The available data suggest that treatment response reflects a multidimensional process, in which clinical improvement, psychological status, and broader psychosocial factors interact to influence patient-reported outcomes. Overall, the reviewed studies indicate that biologic therapies not only reduce disease severity but are also associated with meaningful improvements in health-related quality of life and psychological well-being in patients with psoriasis.